Larimar Therapeutics
study objective to evaluate the safety tolerability and profile of a single ascending dose and multiple ascending doses of in patients aged years with ataxia | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
4 of 15
Related slides by other companies
Oculis
Investor Presentation
July 2023
study objectives | Oculis
Imperial Brands
Investor Presentation
September 2018
| Imperial Brands
Bionomics
Results
March 2023
a phase randomized double blind study to evaluate the efficacy and safety of compared to placebo for the acute treatment of social anxiety disorder | Bionomics
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Investor Presentation
November 2023
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io